SCHEMBL5404352

SCHEMBL5404352

C[CH]OS(=O)(=O)c1cccc(Cl)c1C

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 6/20 0.43
EDNRB P24530 2/20 0.41
EDNRA P25101 2/20 0.41
CCR4 P51679 1/20 0.39
SLC40A1 Q9NP59 1/20 0.39
ALDH1A1 P00352 2/20 0.37
HTR6 P50406 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
TP53 P04637 1/20 0.35
MCOLN3 Q8TDD5 1/20 0.34
KCNH2 Q12809 1/20 0.34
NFE2L2 Q16236 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13290726 0.80 HSD11B1 (0.46) HSD11B1EDNRBEDNRACCR4SLC40A1
SCHEMBL5404356 0.76 HSD11B1 (0.43) HSD11B1EDNRBEDNRACCR4SLC40A1
SCHEMBL7106883 0.75 HSD11B1 (0.51) HSD11B1EDNRBEDNRACCR4SLC40A1
SCHEMBL5742716 0.75 HSD11B1 (0.42) HSD11B1EDNRBEDNRACCR4SLC40A1
SCHEMBL6178321 0.74 KMT2A (0.44) HSD11B1EDNRAALDH1A1HTR6MEN1
SCHEMBL350041 0.74 HSD11B1 (0.50) HSD11B1EDNRBEDNRACCR4SLC40A1
SCHEMBL2046745 0.74 HSD11B1 (0.50) HSD11B1EDNRBEDNRACCR4SLC40A1
SCHEMBL3277048 0.74 HSD11B1 (0.50) HSD11B1EDNRBEDNRACCR4SLC40A1
SCHEMBL5389302 0.73 HSD11B1 (0.41) HSD11B1EDNRBEDNRACCR4SLC40A1
SCHEMBL618887 0.72 HSD11B1 (0.49) HSD11B1EDNRBEDNRASLC40A1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US claimed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US claimed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP claimed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US claimed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO claimed
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US disclosed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US disclosed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP disclosed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US disclosed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885EDNRB 2873/4885EDNRA 3085/4885
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 HSD11B1 1/4885EDNRB 1310/4885EDNRA 1747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.